This immunotoxin was achieved by conjugating/fusing the Anti-CD19 scFv to Diphtheriatoxin. It was expressed in CHO and purified with affinity chromatography. The immunotoxin selectively binds to cancer cells. Once bind, the toxin enters cells by receptor-mediated endocytosis, then Before the N-terminal 193 amino acids corresponding to the catalytic domain of DT enzyme; -II binding and elongation factor into the eukaryotic cell; the cell can catalyze specific elongation factor EF2 amide His699 of diphtheria ADP2 ribosylation occurs; thereby preventing protein synthesis and causes cell death. It was designed for treatment of Head and neck squamous cell cancer or bladder cancer.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.